Current issues in techniques of prostate brachytherapy

Seminars in Surgical Oncology

Volumn 13, Issue 6, 1997, Pages 444-453

  Nori, Dattatreyudu ^a,b   Moni, Janaki ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Brachytherapy; Patient selection; Prostate specific antigen; Prostatic neoplasms; Radioisotopes; Survival rate; Ultrasonography; X ray computed tomography

Indexed keywords

ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER INVASION; CANCER SURVIVAL; DOSE CALCULATION; FLUOROSCOPY; HORMONAL THERAPY; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SCREENING; SURVIVAL RATE; TUMOR VOLUME;

ACTUARIAL ANALYSIS; ADENOCARCINOMA; AGED; BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; MALE; PATIENT SELECTION; PROSTATIC NEOPLASMS; RADIOTHERAPY, HIGH-ENERGY; RISK FACTORS;

EID: 0030831370     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199711/12)13:6<444::AID-SSU9>3.0.CO;2-A     Document Type: Article

References (46)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. CA J Clin 1997;47:5-27.
2. Pasteau O, Degrais P: The radium treatment of cancer of the prostate. Arch Roentgen Ray 1914;28:396-410.
3. Flocks RH, Kerr HD, Elkins HB, Culp DA: Treatment of carcinoma of the prostate by interstitial radiation with radioactive gold (Au-198): a preliminary report. J Urol 1952;68:510-522
4. Whitmore WF Jr, Hilaris B, Grabstald H: Retropubic implantation of iodine-125 in the treatment of prostatic cancer. J Urol 1972;108:918-920.
5. Fuks Z, Leibel SA, Wallner KE, et al: The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125-iodine implantation. Int J Radiat Oncol Biol Phys 1991;21:537-547.
6. Charyulu KK: Transperineal interstitial implantation of prostate cancer: a new method. Int J Radiat Oncol Biol Phys 1980;6:1261-1266.
7. Holm HH, Juul N, Pedersen JF, et al: Transperineal 125iodine seed implantation in prostate cancer guided by transrectal ultrasonography. J Urol 1983;130:283-286.
8. Terris MK, Stamey TA: Determination of prostate volume by transrectal ultrasound. J Urol 1991;145:984-987.
9. Stock RG, Stone NN, Wesson MF, DeWyngaert JK: A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 1995;32:219-225.
10. Grimm PD, Blasko JC, Ragde H: Ultrasound-guided brachytherapy for transperineal implantation of iodine-125 and palladium-103 for treatment of early stage prostate cancer. Atlas Urol Clin North Am 2:113-125.
11. Osian AD, Nori D: Conformal brachytherapy of carcinoma of the prostate. Endocuriether/Hypertherm Oncol 1994;10:15-24.
12. Wallner K: Iodine-125 brachytherapy for early stage prostate cancer: new techniques may achieve better results. [Review] Oncology 1991;5:115-122, discussion 122.125-126.
13. Wallner K, Roy J, Harrison L: Tumor control and morbidity following transperineal iodine 125 implantation for Stage T1/T2 prostatic carcinoma. J Clin Oncol 1996;14:449-453
14. Blasko JC, Wallner K, Grimm PD, Ragde H: Prostate specific antigen based disease control following ultrasound guided 125-iodine implantation for stage T1/T2 prostatic carcinoma. J Urol 1995;154:1096-1099.
15. Langlotz CP. Benefits and costs of MR imaging in prostate cancer. [Review] MRI Clin North Am 1996;4:533-544.
16. Tempany CM, Zhou X, Zerhouni EA, et al: Staging of prostate cancer, results of Radiology Diagnostic Oncology Group project comparison of three ME imaging techniques. Radiology 1994; 192:47-54
17. Anderson LL: Spacing nomograph for interstitial implants of 125-I seeds. Med Phys 1976;3:48-51.
18. Anderson LL, Moni JV, Harrison LB: A nomograph for permanent implants of palladium-103 seeds. Int J Radiat Oncol Biol Phys 1993;27:129-135.
19. Roy JN, Wallner KE, Harrington PJ, et al. A CT-based evaluation method for permanent implants: application to the prostate. Int J Radiat Oncol Biol Phys 1993;26:163-169.
20. 125I prostate implants. Int J Radiat Oncol Biol Phys 1996;34:717-725.
21. Wallner K, Roy J, Harrison L, et al: Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 brachytherapy. Int J Radiat Oncol Biol Phys 1995;32:465-471.
22. Carlton CE, Scardino PT: Combined interstitial and external radiation for prostate cancer. Proceedings of the Second International Symposium on Prostate Cancer; 1986 June 16-18; Paris, France. Prog Clin Biol Res 1987;243B:141-162.
23. Nag S, Sweeney PJ, Wiendjes MG: Dose response study of iodine 125 and palladium 103 brachytherapy in a rat prostate tumor (NBA1-1). Endocuriether/Hypertherm Oncol 1993;9:97-104.
24. Nag S, Ribovich M, Cai JZ, et al: Palladium 103 versus Iodine 125 brachytherapy in the Dunning-Pap rat prostate tumor. Endocuriether/ Hypertherm Oncol 1996;12:119-124.
25. Ling CC: Permanent Implants Using Au-198, Pd-103 and I-125. Radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 1992;23:81-87.
26. Lerner SP, Seale-Hawkins C, Carlton CE Jr, Scardino PT: The risk of dying of prostate cancer in patients with clinically localized disease. J Urol 1991;146:1040-1045.
27. Mason DL, Battista JJ, Barnett RB, Porter AT: Ytterbium-169: calculated physical properties of a new radiation source for brachytherapy. Med Phys 1992;19:695-703.
28. Martinez A, Edmundsen GK, Cox RS, et al: Combination of external beam radiation and multiple-site perineal applicator (MUPIT) for the treatment of locally advanced or recurrent prostatic, anorectal, and gynecologic malignancies. Int J Radiat Oncol Biol Phys 1985;11:391-398.
29. Puthawala AA, Syed AM, Tansey L: Temporary Iridium-192 implant in the management of carcinoma of the prostate. Endocurietherap/Hypertherm Oncol 1985;1:25-33.
30. Martinez A, Gonzalez J, Stromberg J, et al: Conformal prostate brachytherapy: initial experience of aphase I/II dose-escalating trial. Int J Radiat Oncol Biol Phys 1995;33:1019-1027.
31. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
32. Pilepich MV, Krall JM, Sause WT, et al. Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate - analysis of RTOG study 75-106. Int J Radiat Oncol Biol Phys 1987;13:351-357.
33. rd, Kuban DA, et al: Morbidity and mortality of local failure after definitive therapy for prostate cancer J Urol 1989;141:567-571.
34. Mortin JD, Peschel RE: Iodine-125 implants versus external beam therapy for stages A-2, B, and C prostate cancer. Int J Radiat Oncol Biol Phys 14;1153-1157, 1988.
35. Stone NN, Ramin SA, Wesson MF, et al: Laparoscopic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed prostate. [comment in: J Urol 1995;153:1570-1571] J Urol 1995;153:1555-1560
36. Partin AW, Yoo J, Carter HB, et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological state in men with localized prostate cancer. [comment in: J Urol 1993;150:1923-1924; comment in: J Urol 1994;152:172-173] J Urol 1993;150:110-114.
37. Bastacky SI, Walsh PC, Epstein JI: Relationship between perineural tumor invasion and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate. Am J Surg Path 1993;17:336-341.
38. McNeal JE, Villers AA, Redwine EA, et al: Histocytologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990;66:1225-1233.
39. Peller PA, Young DC, Marmaduke DP, et al: Sextant prostate biopsies. A histopathological correlation with radical prostatectomy specimens. Cancer 1995;75:530-538.
40. Ackerman DA, Barry JM, Wicklund RA, et al: Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 1993;150:1845-1850.
41. Loch T, McNeal JE, Stamey TA: Interpretation of bilateral positive biopsies in prostate cancer. J Urol 1995;154:1078-1083.
42. Kleinberg L, Wallner K, Roy J, et al: Treatment-related symptoms during the first year following transperineal 125-I prostate implantation. Int J Radiat Oncol Biol Phys 1994;28:985-990.
43. Dattoli M, Wallner K, Sorace R, et al: 103-Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys 1996;35: 875-879.
44. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. [comment in: J Urol 1994;152 (5 Pt 2):1816] J Urol 1994;152 (5 Pt 2):1831-1836.
45. Catalona WJ, Biggs SW: Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 1990;143:538-544.
46. Hanks GE: External beam radiation therapy for clinical localized prostate cancer: patterns of care studies in the United States. [Review] NCI Monogr 1988;7:75-84.